India markets open in 28 minutes

Knight Therapeutics Inc. (GUD.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
6.00-0.04 (-0.66%)
At close: 4:00PM EDT
Full screen
Previous close6.04
Open6.04
Bid5.99 x 0
Ask6.01 x 0
Day's range5.97 - 6.06
52-week range4.73 - 8.88
Volume180,441
Avg. volume235,977
Market cap785.628M
Beta (5Y monthly)0.76
PE ratio (TTM)146.34
EPS (TTM)0.04
Earnings date13-Aug-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.74
  • GlobeNewswire

    Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®

    MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus. VMS are commonly known as hot flashes or flushes and night sweats. VMS affect 60% to 80% of women entering menopause.1 BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada. The two hormones included in BIJUVA have the same structure as the hormones produced and circulating in the woman’s body. In the U.S., BIJUVA is marketed by TherapeuticsMD and is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.“We are pleased to be able to offer a new treatment for postmenopausal women to address challenging symptoms of hot flashes and night sweats with BIJUVA.” said Samira Sakhia, President and Chief Operating Officer of Knight.“The approval of BIJUVA by Health Canada is a significant accomplishment by Knight, adding to the earlier approval of IMVEXXY® in August 2020, that offers new treatment options to women in Canada,” said Robert Finizio, Chief Executive Officer of TherapeuticsMD.Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to BIJUVA and IMVEXXY (estradiol vaginal inserts). Under the terms of the license agreement related to BIJUVA in Canada, Knight will pay TherapeuticsMD a milestone fee for the regulatory approval in Canada of BIJUVA, sales milestone fees based upon certain aggregate annual sales of BIJUVA in Canada, and royalties based on aggregate annual sales of BIJUVA in Canada.About BIJUVABIJUVA was developed and approved in the U.S. for the treatment of moderate to severe VMS due to menopause in women with a uterus. It is a combination of 1 mg bio-identical estradiol and 100 mg bio-identical progesterone in a once-daily oral softgel capsule.In Canada, BIJUVA is available as a once-daily capsule in two strengths; 1 mg estradiol/100 mg progesterone and 0.5 mg estradiol/100 mg progesterone.Please see the Full BIJUVA and IMVEXXY Canadian Product Monographs available at https://www.gud-knight.com.Please see U.S. Full Prescribing Information for BIJUVA, including BOXED WARNING for cardiovascular disorders, breast cancer, endometrial cancer and probable dementia, available at https://www.bijuva.com/pi.pdf.Please see U.S. Full Prescribing Information for IMVEXXY, including BOXED WARNING for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, available at www.imvexxy.com/pi.pdf.About Knight Therapeutics Inc.   Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.Forward-Looking Statements for Knight Therapeutics Inc.This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.About TherapeuticsMD, Inc. TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.Forward-Looking Statements for TherapeuticsMD Inc. This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: https://ir.therapeuticsmd.com/press-releases.References: 1. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197–214 CONTACT INFORMATION:Knight Therapeutics Inc. Samira Sakhia President and Chief Operating Officer T: 514-514.484.4483 F: 514-481-4116 info@gudknight.com www.gudknight.com Arvind Utchanah Chief Financial Officer T. 514.484.4483 F. 514.481.4116 Email: info@gudknight.com Website: www.gud-knight.comTherapeuticsMD Nichol Ochsner Vice President, Investor Relations 561-961-1900, ext. 2088 Nochsner@TherapeuticsMD.com

  • GlobeNewswire

    Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

    MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX was originally approved by Health Canada in July 2019 for the extended adjuvant treatment of women with early stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.1The SNDS is supported by the results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with ≥ 2 HER2-directed regimens.“We’re excited to submit a new indication of NERLYNX to Health Canada, enabling us to offer a new targeted treatment option for Canadian women and physicians,” said Samira Sakhia, President and Chief Operating Officer at Knight Therapeutics.Knight and Puma Biotechnology, Inc. (NASDAQ: PBYI) signed a licensing agreement in January 2019 granting Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada.About HER2-Positive Breast CancerUp to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease). HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death2. About 6.6%-8% of HER2-positive breast cancer is metastatic disease based on a Canadian population study3. The median overall survival for metastatic HER2-positive patients is 28.1 months from a contemporary population-based study4. About NALAThe NALA trial is a randomized controlled Phase III trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients with ≥ 2 previous HER2-directed therapies . The trial enrolled 621 patients who were randomized (1:1) to receive either neratinib plus capecitabine or lapatinib plus capecitabine. The trial was conducted globally at sites in North America, Europe, Asia-Pacific and South America. The co-primary endpoints of the trial are centrally confirmed progression free survival (PFS) and overall survival (OS). Treatment with neratinib in combination with capecitabine resulted in a statistically significant improvement in PFS (Hazard Ratio 0.76; 95% CI: 0.63, 0.93; p=0.0059) compared to treatment with lapatinib plus capecitabine.The most common adverse reactions of any grade (>5%) in the neratinib plus capecitabine arm were diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms. The most frequently reported Grade 3 or 4 adverse reactions were diarrhea, nausea, vomiting, fatigue and decreased appetite.The recommended neratinib dose for advanced or metastatic breast cancer is 240 mg (6 tablets) given orally once daily with food on days 1-21 of a 21-day cycle plus capecitabine (750 mg/m2 given orally twice daily) on days 1-14 of a 21-day cycle until disease progression or unacceptable toxicities5.About Knight Therapeutics Inc.Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pan-American (ex-US) specialty pharmaceutical company focused on developing, acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.Forward-Looking StatementThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. For further information, please contact:Knight Therapeutics Inc. Samira Sakhia President and Chief Operating Officer T: 514-678-8930 F: 514-481-4116 Email: info@gudknight.com Website: www.gud-knight.com Knight Therapeutics Inc. Arvind Utchanah Chief Financial Officer T. 514.484.4483 ext. 115 F. 514.481.4116 Email: info@gudknight.com Website: www.gud-knight.com References 1. NERLYNX® Product Monograph, September 17, 2019 2. Slamon DJ, et, al. Science 1987; 235:177–182. 3. Elizabeth Hammonda, et al. Cancer Epidemiology 45 (2016) 82–90. 4. Benjamin Daniels, et al. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-018-4804-0 5. Cristina Saura, et al. J Clin Oncol 38. DOI: 10.1200/JCO.20.00147

  • Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
    Business Wire

    Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

    Approval of IMVEXXY by Health Canada announced by TXMD and Knight Therapeutics.